Herpes Simplex Meningo EncephalitisNCT06627010
Herpes Simplex Meningo Encephalitis Recurrence
An observational study of Herpes Simplex Meningo Encephalitis, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
study of risk factors and prognosis of herpes simplex encephalitis recurrence. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Herpes Simplex Meningo Encephalitis
- What is being tested?
- description
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2012to 28 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Herpes Simplex Meningo Encephalitis Recurrence
Who may be able to join
- documented herpes simplex recurrence
Who cannot join
- other cause
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Chru Nancy
Vandœuvre-lès-Nancy, 54500
Valentin HESS, v.hess@chru-nancy.fr
About this study
study of risk factors and prognosis of herpes simplex encephalitis recurrence.
- Conditions
- Herpes Simplex Meningo Encephalitis
- Being tested
- description
- Medical subject headings
- Encephalitis, Herpes Simplex
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
descriptionOther
study of file
What is being measured
The primary outcome is the main question the study is designed to answer.
survival rate
prognosis
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2024
- Study start1 Jan 2012
- Primary completion1 Jan 2012
- Study completion28 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Herpes Simplex Meningo EncephalitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, HESS Valentin, Central Hospital, Nancy, France
- Investigators
- Valentin HESS, Principal investigator, CHRU NANCY
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06627010
- Sponsor's protocol ID
- 2023PI237
- Status last verified
- Jan 2024
- First submitted
- 26 Jan 2024
- Last updated
- 4 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: anonymous
Study at a glance
From the registry record, last updated by the sponsor on 4 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Herpes Simplex Meningo Encephalitis Recurrence
- ClinicalTrials.gov ID
- NCT06627010
- Acronym / sponsor ID
- 2023PI237
- Conditions
- Herpes Simplex Meningo Encephalitis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 1 Jan 2012 (actual)
- Study completion
- 28 Jan 2025 (estimated)
- First posted
- 4 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
study of risk factors and prognosis of herpes simplex encephalitis recurrence.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Herpes Simplex Meningo Encephalitis Recurrence
Key inclusion criteria (1 listed)
- documented herpes simplex recurrence
Key exclusion criteria (1 listed)
- other cause
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| descriptionstudy of file | Other | – |
Primary outcome
survival rate
Time frame: 1 year
prognosis
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Oct 2024.
- Individual participant dataSharing planned: No. anonymous
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Valentin HESS principal investigator
CHRU NANCY
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Herpes Simplex Meningo Encephalitis, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Valentin HESS, MD (0383153615 ext. +33, v.hess@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
survival rate (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2024.